Description
The Seraseq Tri-Level Tumor Mutation DNA Mix v2 (HC) is a multiplexed mixture of actionable biosynthetic DNA targets precisely blended with a single, well-characterized genomic background. This product is produced under rigorous design control and manufacturing practices, offered in a high concentration (HC) format at 25 ng/µL. Designed to assess the overall performance of your somatic mutation assay by next-generation sequencing (NGS), this unique product offers a range of allele frequencies in a single sample format, including single nucleotide variants (SNVs), insertion-deletion mutations (indels), and structural variants (SVs).
- Single-sample format for daily run use
 - 40 unique multiplexed variants across 28 genes (see table in Specifications tab) at allele frequencies distributed at 4%, 7% or 10%
 - 20 SNVs
 - 5 SNVs that are part of homopolymers
 - 13 indels
 - 2 SVs
 - Mutation targets quantitated with digital PCR
 - Well-characterized GM24385 human genomic DNA as background ‘wild-type’ material
 - Manufactured under cGMP within ISO 9001 and ISO 13485 certified facilities
 
The Seraseq Tri-Level Tumor Mutation DNA Mix v2 (HC) is formulated for use with targeted next-generation sequencing (NGS) assays that detect mutations in key oncogenes and tumor suppressor genes. The Seraseq Tri-Level Mutation DNA Mix v2 (HC) is intended as a quality reference material for translational and disease research testing to monitor library preparation, sequencing, and variant allele detection under a given set of bioinformatics pipeline parameters.
For research use only. Not for use in diagnostic procedures.
Size : 1 x 25 µL
Unit : EA
Specifications:
| Gene List | |||
| AKTI | FGFR3 | JAK2 | PDGFRA | 
| APC | FLT3 | KIT | PIK3CA | 
| ATM | FOXL2 | KRAS | PTEN | 
| BRAF | GNA11 | MPL | RET | 
| CTNNB1 | GNAQ | NCOA4-RET | SMAD4 | 
| EGFR | GNAS | NPM1 | TP53 | 
| ERBB2 | IDH1 | NRAS/CSDE1 | TPR-ALK | 
